Johnson & Johnson
JNJ · NYSE
JNJ · NYSE
Johnson & Johnson is a healthcare company operating in Innovative Medicine and MedTech. Innovative Medicine sells prescription medicines, including oncology therapies such as RYBREVANT; MedTech supplies medical technologies and devices, with Abiomed among the businesses mentioned in the supplied evidence. The company earns revenue from sales of medicines and medical products to patients through healthcare systems, and from products used by clinicians and hospitals. The evidence does not provide a revenue split between the segments. J&J reported FY2025 revenue of $94.2 billion and net income of $26.8 billion, up from $88.8 billion and $14.1 billion, respectively, in FY2024.
Johnson & Johnson rose $7.59, or 2.84%, over the week, from $267.61 to $275.20. Shares dipped to $266.30 on Monday, then advanced on each of the next three sessions, closing at the period high Thursday. The supplied news flow included encouraging early-stage oncology results: a RYBREVANT FASPRO combination showed a 77% response rate in a first-line head-and-neck cancer study, and JNJ-6143 produced promising early data in advanced prostate cancer. Those reports offer potential pipeline support, though the evidence does not establish their effect on daily trading. A counterweight was J&J’s slower Q3 MedTech growth, attributed to international challenges and Abiomed weakness; Erste Group also downgraded the stock to Hold on Tuesday. Shares nevertheless rose through the downgrade.
Johnson & Johnson fell 3.77%, from $263.73 to $253.79. The main move was a sharp, high-volume selloff on October 13, when shares dropped to $248.61 on volume of 16.6 million; a supplied headline reports that JNJ slipped despite a third-quarter earnings beat. Shares then recovered to $255.56 by October 16 before easing to $253.79 on October 19. A separate headline says drug performance lifted guidance, but the supplied evidence does not establish when that news appeared or explain why the earnings beat failed to support the stock. Overall, the week’s decline was driven by the October 13 drop, with most of that loss subsequently pared.
JNJ rose $10.80, or 4.27%, from $252.93 on October 5 to $263.73 on October 12. The stock advanced in five of the six sessions, with a modest reversal on October 8: it climbed from $252.93 to $258.45 through October 7, slipped to $256.48, then recovered to $261.44 on October 9 and added to that gain on October 12. Company coverage highlighted raised 2026 guidance and a Q3 earnings beat, alongside a miss in Medical Device sales; that is a mixed backdrop rather than a clear explanation for the week’s rise. A Yahoo Finance headline also reported $107.4 million of net ETF buying on Wednesday, but the evidence does not establish that these events drove the share-price moves.
JNJ fell 4.78%, from $267.57 to $254.78, over the supplied interval. The decline was persistent through Monday: the stock closed lower on each session from September 30 through October 5, reaching $252.93, before rebounding 0.7% to $254.78 on October 6. Trading volume rose as the stock fell, peaking at 10.9 million shares on October 2. No company-specific announcement in the evidence explains the sustained selling. Zacks noted that JNJ fell on October 5 despite gains in the broader market, while a report cited $69.4 million of ETF selling that day; neither establishes a fundamental cause. Upcoming Q3 previews and discussion of psoriasis data appeared in the news flow, but the supplied evidence does not tie them to the weekly move.
JNJ fell 0.60%, from $269.19 to $267.57, though the daily closes show a sharp reversal late in the period. The stock rose from $269.19 on September 22 to $271.95 on September 28, then dropped to $267.57 on September 29. Johnson & Johnson reported new two-year IMAAVY data in adolescents with generalized myasthenia gravis, showing sustained disease control and improvements in daily function and muscle strength, alongside reduced corticosteroid use. The supplied evidence does not establish that this update drove the selloff; it also provides no broader-market performance to explain the move. Zacks separately reported a 1.58% one-day decline, citing a different closing price of $267.66.
JNJ gained 0.71%, rising from $267.28 on September 16 to $269.17 on September 23. The move came chiefly with a $2.94 advance on September 17 to $270.22; the shares then eased slightly on September 18 and drifted lower through September 23, giving back most of that one-day rise. Trading volume peaked at 16.4 million shares on September 18, but the supplied evidence does not explain the higher activity. Reports describe progress in TREMFYA’s 411-person study and encouraging long-term myeloma analyses, but provide no timing that links those updates to the daily moves. No market or sector benchmark is provided to explain the otherwise modest net gain.
JNJ fell $8.91, or 3.24%, from $275.23 to $266.32 across the supplied period. The decline was concentrated in the move to $269.12 on September 8, when volume rose to 8.1 million shares, and continued through September 11, when the stock closed at $265.58. It then recovered modestly to $266.32 on September 14, leaving it near the period low. The supplied evidence identifies no company-specific announcement, earnings update, analyst action, or market catalyst tied to these sessions, so the trading pattern appears to reflect selling pressure followed by a limited rebound rather than a documented fundamental repricing. No broader market context is provided to explain the move.
Johnson & Johnson rose 1.23%, from $265.85 to $269.12, despite a sharp late-week reversal. The stock climbed for three straight sessions, reaching $278.43 on September 3, before retreating to $275.23 on September 4 and giving back most of the advance in the September 8 session. The supplied evidence does not identify one dominant company-specific catalyst, although coverage highlighted JNJ’s device-business moves, a CE marking for a product, encouraging ACUVUE lens testing, and Phase 3 bipolar-mania data. Valuation commentary was mixed, with Simply Wall St. calling cash flow attractive but earnings fully priced and GuruFocus labeling the shares 38.3% overvalued. The September 8 decline was described as larger than the broader market’s dip.
JNJ rose $12.66, or 4.76%, from $265.77 to $278.43 over the week. The shares initially slipped 0.8% on Monday, then advanced for three consecutive sessions, gaining $5.34 on Tuesday, $4.02 on Wednesday and $3.22 on Thursday to finish at a record level. The most concrete company-specific catalyst was UBS assuming coverage with a Buy rating, while coverage also highlighted J&J’s participation in a broader healthcare-sector rally. ETF-related demand was another supportive factor, with JNJ among holdings associated with a notable iShares Russell 1000 Value ETF inflow. Broader conditions were constructive as crude oil prices and bond yields eased, helping stabilize stocks. No earnings release or new company guidance was reported during the week.
Johnson & Johnson fell $1.60, or 0.60%, from $267.37 to $265.77 over the week. The stock initially advanced, gaining to $273.04 on Monday and $273.14 on Tuesday, before reversing lower as Wednesday's close dropped to $270.00 and Thursday extended the decline to $265.77. The week's main company-specific catalyst was the FDA approval of Imaavy for patients aged 12 and older with warm autoimmune hemolytic anemia, making it the first treatment specifically indicated for the rare disease. The approval produced little lasting support, however, with J&J's shares giving back the early-week gains. Available evidence does not identify another company-specific event or broader-market driver explaining the late-week selling.
Johnson & Johnson rose $5.29, or 2.02%, from $262.08 to $267.37 over the week. The stock edged up Monday, then jumped 3.33% Tuesday and added 0.85% Wednesday as investors responded to product developments, including FDA 510(k) clearance for the MONARCH QUEST 3 robotic-bronchoscopy update and European approval of the TECVAYLI-daratumumab combination for relapsed or refractory multiple myeloma. JNJ gave back most of its midweek advance Thursday, falling 2.21% to $267.37. The supplied evidence does not identify a broader market catalyst or a company-specific explanation for Thursday’s reversal. Trading volume increased materially on the rally and remained elevated during the decline.
Johnson & Johnson rose 2.91%, from $254.41 to $261.81 over the supplied interval, advancing on four of five sessions and finishing at the period high. The move was steady rather than reversal-driven: shares edged up to $254.93 on Tuesday, gained 1.0% Wednesday, slipped $0.61 Thursday, then added $2.23 Friday and $2.57 on Monday. Monday volume increased to 8.99 million shares from 8.14 million at the period start. The supplied evidence does not establish a specific company announcement or analyst action as the decisive weekly catalyst. Instead, investor attention appears to have included broader discussion of a pharmaceutical recovery, J&J’s $5.5 billion talc settlement, leadership changes, and a cancer drug priority review.
Johnson & Johnson fell $11.80, or 4.42%, from $266.73 to $254.93 over the week. The decline was concentrated in the $9.71 drop on July 30, followed by a modest rebound on July 31, another $1.94 loss on August 3, and a $0.52 recovery on August 4. The supplied evidence does not identify a dated earnings release, guidance change, or other company-specific shock that explains the move. Instead, market context included a Dow milestone and an AI-driven technology sell-off, with JNJ cited among non-technology blue chips supported by earnings growth. Positive company themes—oncology growth, OTTAVA commercialization, and a reported JNJ-GSK deal—did not prevent the stock from weakening.
